Chart, page-728

@Medicca71

Success for AusCann will be formulating medicinal cannabis products that treat chemotherapy-induced nausea, treatment-resistant childhood epilepsy, palliative care symptoms, and last but by no means least, chronic pain.


Its use in chronic pain is something which we have a keen eye on.

Although a smaller market than in Canada, A$5.8 billion is still not to be sniffed at.

If medicinal cannabis can become the dominant treatment option for chronic pain in Australia, then AusCann stands to benefit greatly.